Next Phase Newsletter

A venture capital firm makes around 1/3 of its investments in industry tech mainly focusing on digital transformation within traditional sectors, second 1/3 in enterprise tech including both SaaS and network technology, and the last 1/3 in healthcare, including AI in healthcare and medical devices. The firm manages 3 funds right now, and the latest fund closed in 2022. The firm typically invests $1M-$2M initial check per company,  and reserve 2/3 of the fund for pro rata. The firm prefers to lead the round and also open to co-investment. The firm typically makes 7-10 new investments per year, and only focuses on companies based in North America (USA & Canada). Furthermore, the firm has a considerable value-add in supporting companies leveraging their former entrepreneur and operator experience, and their CXO network which includes over 30 executives from Fortune 1000 companies. 
 
The firm is open to all subsectors of AI in healthcare, diagnostics and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage. 
 
The firm does not have a particular management team requirement, as it primarily assesses the technology itself. If leading the round, the firm will take a board seat after an investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A leading alternative asset manager in Europe – investing in early-stage VC, growth VC, venture debt, strategic equity in listed companies, infrastructure and private equity – providing financing solutions to companies throughout their life-cycle. Founded in 2008, the firm counts on 210 active companies, 64 exits and more than €1,2bn of assets under management. Some of the firm’s portfolio companies have been acquired by multinationals such as Intel, Symantec, IBM, and Facebook, whilst others are listed in public markets such as NASDAQ, the Spanish BME Growth, AIM London, and Euronext Growth. 
 
In the life sciences, the firm focuses on therapeutics and also CDMOs, medical devices, healthcare and Digital Health. In therapeutics, the firm focuses on preclinical opportunities with a focus on assets that are 12-18 months prior to IND. The firm generally does not invest in large indication areas such as diabetes, metabolic disease, cardiovascular and renal disease. Outside of Therapeutics, the firm invests in companies that are revenue positive. Ticket sizes range from 1-5M€. 
 
In therapeutic opportunities, the firm seeks companies that have obtained proof of concept data in animal studies and can reach human clinical trials with financial needs of up to EUR 15million to reach a human Proof of Efficacy. In Spain, the firm typically leads investment rounds, and may syndicate with other firms or leverage public funding. Outside of Spain, the firm seeks to co-invest in rounds led by local top-tier Venture Capital. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm is part of a large investment holding company with over €25 billion in assets under management. The firm actively seeks early-stage investment opportunities in global companies that offer disruptive therapeutic approaches across modalities and disease areas, specifically addressing unmet medical needs. The firm offers evergreen support until key value-added milestones and meaningful impact are achieved. Investment sizes typically range from 1 to 10 million euros, with the capacity for larger follow-on investments in portfolio companies. The firm is open to participation at any stage, with a preference for Seed to Series B rounds. The firm’s willingness to lead or co-invest extends to companies in Spain and Portugal, and the firm also participates as a co-investor globally, with a special focus on the EU.

The firm is a flexible and opportunistic investor that is currently considering disruptive therapeutics companies in areas of unmet need. The firm will look at opportunities of all stages from pre-clinical to phase I/II.

The firm will invest in privately held companies only. The firm seeks companies with a full-time management team with expertise, successful track records would be a plus but is not required. The firm takes a board seat in portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A private equity fund in China mainly focuses pharmaceuticals, medical device & diagnostic, and healthcare services. The firm typically makes equity investments of US$5-10 million per deal over a 5-6 year exit horizon. The firm is open to leading or co-investing. The firm is investing from its RMB and USD funds and is currently seeking opportunities from China and the U.S.

The firm has a clearly defined investment focus primarily on three healthcare subsectors: Pharmaceuticals, Medical Device & Diagnostic, and Medical Service. Within pharmaceuticals, the firm considers chemical drugs in Oncology, Cardiovascular, Gastrointestinal, second generation drugs, brand generics, OTC, drug delivery platforms, CRO/CMO; biotech products in Biosimilar, Vaccines, blood product, etc.; and Traditional Chinese Medicine (TCM). The firm prefers first-in-class projects in phase I or IIa with safety and efficacy data. Within Medical Device and Diagnostics, the firm is interested in High-end devices, Consumables, Implantable Devices and Interventional Devices with high-technical barrier, Molecular Diagnostics, Immunological Diagnostics, and Genetic Diagnostics. The firm is especially interested in medical robotics and AI. In addition, the firm would consider R&D services that support cell therapy, stem cell, and new therapies. For 505b2 drugs or medical devices, the firm considers from preclinical to pre-IND stages.

The firm is looking for experienced management teams with sector expertise. Within China, the firm prefers companies with approved products and sales track record. Within the U.S., the firm can consider earlier stage companies depending on the business model and exit strategy. The firm’s GP has a strong network in China and can offer assistance in distribution and registration. For therapeutics, the firm prefers companies who have completed Phase 1 and Phase 2a trials and can show some safety and efficacy data.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.